Tuesday, April 26, 2016

Meta-Analysis Suggests Nutraceuticals May Be Effective Adjuncts to Antidepressants


Several commercially sold “nutraceutical” compounds—including S-adenosylmethionine (SAMe), methylfolate, omega-3, and vitamin D—may be effective adjuncts to antidepressants for reducing depressive symptoms, according to a meta-analysis published today in AJP in Advance.

Australian and American investigators searched the literature up to December 2015 for clinical trials that examined any adjunctive nutrient-based intervention for depression and identified 40 studies (31 were randomized, double-blind, and placebo-controlled trials) for analysis. Common trial lengths were 4, 6, and 8 weeks, with a mean sample size of 63 participants and a mean age of 44 years for analysis; a variety of antidepressant pharmacotherapies were used in the studies, which primarily used open inclusion of all SSRIs or commonly specified prescription of fluoxetine, citalopram, or escitalopram.

Statistical analysis revealed a positive effect of the adjunctive intervention in 68% of the clinical trials. The authors reported positive results for replicated studies testing S-adenosylmethionine (SAMe), methylfolate, omega-3 (primarily EPA or ethyl-EPA), and vitamin D, with positive isolated studies for creatine, folinic acid, and an amino acid combination. Mixed results were found for zinc, folic acid, vitamin C, and tryptophan, with nonsignificant results for inositol.

“All of the nutraceuticals reviewed in this article have mechanistic antidepressant activity underpinning their use,” the authors wrote. For instance, omega-3 appears to exert “antidepressant activity potentially through modulation of norepinephrine, dopamine, and serotonin reuptake, degradation, synthesis, and receptor binding; through enhancement of glutathione antioxidant capacity; and through enhancement of cell membrane fluidity.” The anti-inflammatory properties of the compounds examined may also contribute to their antidepressant efficacy, the researchers added.

“Nutraceutical applications in psychiatry are advancing, as reflected in recent international collaborative consensus and position statements discussing the potential of nutraceutical use in psychiatry,” the researchers stated. “[M]uch more work is needed, and while an evolving body of research is strengthening the potential of nutraceuticals (and dietary considerations) as an important element in modern psychiatric practice, we are only beginning to study their potential applications.”

For related information, see the Psychiatric News article “Food May Be a Tool to Consider When Helping Psychiatric Patients.”

(Image: iStock/Bet_Noire)

Disclaimer

The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.